Acurian Quickly Closes a Critical Enrollment Gap for an IBS Study

Gastroenterology

IBS

This small pharmaceutical company was in a race to be first to market for diarrhea-predominant Irritable Bowel Syndrome (IBS), a market with multi-billion dollar potential. An 11-month enrollment timeline was critical to the successful completion of a two-protocol, phase III program.

Read More »